ArticleFrontiers in pharmacology2022
Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Median effective dose (EDBMC anesthesiology · 2026Trial
- Esketamine Use and Attempted Suicide or Intentional Self-Harm Among Individuals with Treatment-Resistant Depression: A Retrospective Cohort Study.Drug safety · 2026Article
- A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals.European journal of clinical pharmacology · 2025Article
- The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.Molecular psychiatry · 2025Review
- The post-marketing safety of Esketamine among older adults(≥ 65): an real-world pharmacovigilance study.BMC pharmacology & toxicology · 2025Article
- The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database.European archives of psychiatry and clinical neuroscience · 2025Article
- Safety Profile and Suicidality Associated with the Use of Esketamine in the Treatment of Major Depressive Disorder in European Countries: An EudraVigilance Database Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Safety assessment of Edaravone: A real-world adverse event analysis based on the FAERS Database.PloS one · 2025Article
- Is there a risk of esketamine misuse in clinical practice?Therapeutic advances in drug safety · 2025Review
- Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database.Frontiers in pharmacology · 2025Article
- The perspectives of patients with depression toward esketamine, and the influence of their medication adherence on their viewpoints: a Saudi cross-sectional study.Frontiers in psychiatry · 2025Article
- Safety assessment of asenapine in the FAERS database: real adverse event analysis and discussion on neurological and psychiatric side effects.BMC pharmacology & toxicology · 2024Article
- Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database.Frontiers in pharmacology · 2024Article
- Challenges for esketamine nasal spray in China: use and management.Frontiers in pharmacology · 2024Article
- Article
- Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.CNS neuroscience & therapeutics · 2023Article
- Article
- Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.Frontiers in immunology · 2023Article
- The median effective concentration of propofol in combination with different doses of esketamine during gastrointestinal endoscopy in adults.Frontiers in pharmacology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esketamine was approved for the treatment of treatment-resistant depression in 2019. After the approval of esketamine, numerous concerns have been raised regarding its long-term safety and tolerability. A previous systematic pharmacovigilance study on esketamine-related adverse events (AEs) was published in 2020; however, it has not been updated 2 years later. The primary aim of this study was to detect and characterize neurological safety signals of esketamine to partially update the knowledge in this field using the FDA pharmacovigilance database. Reporting odds ratio (ROR) was calculated for esketamine-related neurological AEs from 2019 to 2021 with a signal considered when the lower limit of the 95% confidence interval (CI) of ROR (ROR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.